Medtrum's High-Capacity Pump Aims to Reshape German Diabetes Care

BERLIN, GERMANY – July 20, 2026 – In a calculated move poised to impact one of Europe's largest medical technology markets, global diabetes tech company Medtrum is advancing the German launch of its 300-unit (300U) tubeless patch pump. Following a prominent feature at the DDG 2026 diabetes congress in Berlin, the device has secured a critical listing in Germany's statutory health insurance medical aids directory, signaling a clear path to patient access and reimbursement.

This development is more than a simple product launch; it represents a strategic push into a highly competitive and lucrative market, offering a tangible solution for a specific, underserved patient population while bolstering Medtrum's integrated diabetes management ecosystem.

A Strategic Play in a Key Market

Germany's diabetes technology market is a formidable landscape, estimated to be worth over USD 2.4 billion in 2025 and projected to exceed USD 3.4 billion by 2031. With over 7.8% of the adult population living with diabetes, the demand for advanced management solutions is robust and growing. For any company, entering this market is a significant undertaking, but succeeding requires more than just innovative technology—it requires navigating a complex reimbursement system.

Medtrum has achieved a crucial milestone by having its 300U pump listed in the Hilfsmittelnummer directory. This dedicated product code is the key that unlocks access to Germany's statutory health insurance (GKV) system, which covers over 90% of the population. Without this listing, even the most groundbreaking device remains out of reach for the vast majority of patients. This inclusion validates the pump's clinical utility and paves the way for widespread adoption.

The company’s move directly challenges established players in the tubeless pump space, most notably Insulet with its Omnipod system. By introducing a pump with 50% greater insulin capacity than the commonly used 200-unit models, Medtrum is targeting a clear clinical need. This higher capacity is a significant differentiator, especially as the prevalence of Type 2 diabetes and associated insulin resistance rises.

"Germany is one of Europe's leading diabetes technology markets, with strong clinical adoption, an established reimbursement framework and continued innovation," said Scott Yang, founder and CEO of Medtrum. "The planned introduction of our 300U patch pump reflects our commitment to patient-centered treatment options. By strengthening our direct commercial operations, building partnerships and generating clinical evidence, we aim to support broader patient access and sustainable growth across Europe."

Empowering Patients with Greater Needs

Beyond market strategy, the tangible impact of the 300U pump lies in its user-centric design. For individuals with diabetes who require large daily insulin doses—often those with Type 2 diabetes or significant insulin resistance—a standard 200-unit pump may need to be changed daily. This frequent replacement schedule is not only inconvenient but also creates a constant, intrusive reminder of their condition. It adds to the physical and mental burden of diabetes management.

The 300U reservoir directly addresses this pain point, extending the time between site changes and reducing the number of supplies a user must carry. This seemingly simple increase in capacity can translate into greater freedom, fewer interruptions to daily life, and a reduced cognitive load. It aligns with the theme Medtrum promoted at DDG 2026: "Medtrum macht mehr möglich" ("Medtrum makes more possible").

This patient-first approach is further embedded in the pump's parent platform, the TouchCare Nano System. The system features an "Auto Meal Handling" function, which allows users to announce a meal type (e.g., low-carb, high-fat) rather than performing a precise carbohydrate calculation for every meal. For anyone who has lived with the relentless math of diabetes, this simplification represents a profound improvement in quality of life, making the use of an automated insulin delivery (AID) system more manageable and less error-prone.

Real-world data is beginning to support the efficacy of Medtrum's integrated approach. Results from the French PIM'SS registry, which tracked users of the TouchCare Nano pump, showed an average 5.3 percentage point increase in Time in Range (TIR)—a key metric for glycemic control—with no reported instances of severe hypoglycemia after three months. Such evidence is critical for building confidence among clinicians and patients alike.

The Integrated Ecosystem Approach

The launch of the 300U pump is not about a standalone device but about strengthening a comprehensive, integrated ecosystem. The TouchCare Nano System combines the tubeless patch pump with continuous glucose monitoring (CGM), a proprietary AID algorithm (APGO®), and mobile app control. This platform approach reflects a broader trend in MedTech: moving away from siloed devices toward interconnected systems that automate and simplify chronic disease management.

By controlling the entire technology stack, Medtrum can ensure seamless communication between the glucose sensor, the insulin pump, and the predictive algorithm. The APGO® algorithm is designed to smooth out glucose variability and proactively adjust insulin delivery, reducing the need for constant user intervention. A prospective clinical study (RENEW) is currently underway in the Czech Republic to further evaluate the real-world performance of this algorithm, generating the kind of robust clinical evidence needed for broader European adoption.

This strategy is already paying dividends globally. The company's overseas revenue grew by an explosive 227.2% in 2025, surpassing its domestic revenue for the first time. This success is built on a strong regulatory foundation, including the 2024 attainment of EU MDR Class III certification for the TouchCare AID System—a rigorous standard that many device makers have struggled to meet. As Medtrum prepares for its German launch and engages with stakeholders at upcoming events like the EASD Annual Meeting, its focus remains clear: making diabetes care smaller, simpler, and smarter through deeply integrated technology.